Mental Health & Behavioral Research, Phase II

Valbenazine for Trichotillomania in Adults

Volunteers
Health Professionals

What is the purpose of this trial?

If you are an adult with trichotillomania, you may be eligible to participate in a research study run by the Yale School of Medicine. This study will examine the efficacy of Valbenazine for the treatment of trichotillomania. Valbenazine is a dopamine-depleting agent that is currently FDA-approved for tardive dyskinesia and has a relatively safe side-effect profile in initial trials.

While enrolled in the trial, you will receive regular psychiatric and medical assessments of symptoms at no cost. Additionally, you will receive a stipend of up to $590 over the course of 26 weeks for your participation.

If you are interested in the trial or wish to learn more, please do not hesitate to contact us by phone at 203-432-3940 or 203-737-4809, or email at blochresearch@yale.edu if you have any questions about the trial.

Participate in Research < Child Study Center

Ages
18 years - 65 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Victor Avila-Quintero

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Michael Bloch, MD, MS
Harris Professor in the Child Study Center; Director and Co-Founder of the Pediatric Depression Clinic, Child Study Center; Co-Director of the T32 Postdoctoral Research Fellowship in Childhood Neuropsychiatric Disorders, Child Study Center; Associate Program Director, Albert J. Solnit Integrated Training Program, Child Study Center; Co-Director of the Tic and OCD Program, Child Study Center

Sub-Investigators

Last Updated
11/11/2025
Study IRB
#2000034993